Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment

Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) represents a demyelinating disorder for which tocilizumab, an anti-IL6 receptor, has been tested to prevent disabling relapses. In a subgroup of patients affected with novel Coronavirus disease (COVID-19), tocilizumab has also increased th...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuccio, Fabio Giuseppe, Lo Re, Marianna, Bertolotto, Antonio, Capobianco, Marco, Solaro, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576324/
https://www.ncbi.nlm.nih.gov/pubmed/33296987
http://dx.doi.org/10.1016/j.msard.2020.102592
Descripción
Sumario:Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) represents a demyelinating disorder for which tocilizumab, an anti-IL6 receptor, has been tested to prevent disabling relapses. In a subgroup of patients affected with novel Coronavirus disease (COVID-19), tocilizumab has also increased the survival rate. We present the case of a 31-years-old Caucasian patient who experienced an almost asymptomatic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection during treatment with tocilizumab, which was continued due to the very high risk of relapses of the patient. According to this case, tocilizumab might be not discontinued during COVID-19.

Ejemplares similares